Indiana’s bioscience industry is an innovative and growing component of the overall U.S. economy. With a track record of generating high-quality jobs and steady growth, the bioscience industry has been a consistent engine for our economy and a key strength during past economic recessions. American innovation in bioscience helps support state and local communities in a variety of ways ranging from job creation, construction, tax revenues, and other economic impact values.

Driven by small-company innovators, the bioscience industry has also mobilized in an unprecedented manner to address the global COVID-19 pandemic, while continuing to develop other life-saving and life-enhancing products and services for the U.S. and the world. America’s bioscience industry as an innovator and economic driver has never been more important, both for our health and our economic stability.

Total Number of Facilities in Indiana 29
Jobs Directly Supported by the Industry in Indiana 65290
Annual Average Wage
$109138
Total Clinical Trials
637
Dollar Amount Invested in Clinical Trials
$183.5 Million
Clinical Trial Participants
12152
Total Clinical Trial Economic Impact
$477.6 Million

View Facilities By District

District Total Facilities in District View Facilities in District
IN02 5 Barnes & Thornburg, LLP (O)

Bayer (H)

Cargill, Incorporated (A)

DSM (H)

Poet (A)

IN03 1 Poet (A)
IN04 5 Bayer (H) (4)

DSM (H)

IN05 4 AquaBounty Technologies, Inc. (A)

Bayer (H)

INCOG Biopharma Services, Inc. (O)

Poet (A)

IN06 3 Bayer (H)

Elanco (A)

Sentry Biopharma Services (O)

IN07 9 BioCritica, Inc (H)

Eli Lilly and Company (H)

Eli Lilly and Company (H)

Indiana Health Industry Forum (O)

Lilly Icos LLC (H)

Lilly Research Laboratories (H)

Lilly Ventures (H)

Roche Molecular Diagnostics (H)

Roche Sequencing Solutions, Inc. (H)

IN08 2 Bayer (H)

DSM (H)